49. Daurismo


Active ingredient: glasdegib
Disease: acute myeloid leukemia in adult patients
Peak sales estimate: n/a
Approved: Nov. 21
Company: Pfizer

The scoop: The FDA’s oncology division has been busy with Pfizer filings this fall: Daurismo, approved just before Thanksgiving for certain acute myeloid leukemia (AML) patients, marked the Big Pharma’s fourth FDA-approved NME oncology drug within a two-month period on the backs of Vizimpro, Talzenna and Lorbrena. This latest drug, which comes with a monthly list price of $16,925, is intended for older patients with the blood cancer who can’t tolerate high-dose chemotherapy and who have other conditions. Approval comes from a midstage trial showing that combining Daurismo with a low-dose form of chemo improved overall survival (OS), the golden standard in cancer tests, when compared to taking a low-dose chemo agent on its own. (Median OS was 8.3 months for patients treated with Daurismo-chemo compared with 4.3 months with chemo only.) The National Cancer Institute at the National Institutes of Health reckons about 20,000 people will be diagnosed with AML this year, with almost half unable to be treated with intensive chemo because of side effects or other conditions making it too difficult or dangerous for the patients. — Ben Adams 

49. Daurismo

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.